MiNK Therapeutics, Inc.
NASDAQ:INKTBiotechnology
-$0.35 today
- Market cap
- $52.17M
- Beta
- 0.47
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$2.60
Volume 0.01M
Average 0.05M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
MiNK Therapeutics, Inc.
NASDAQ:INKT
Intrinsic Alpha fair value
Locked
Current Price
$10.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Spruce Biosciences, Inc. NASDAQ:SPRB | $133.79M | $46.55 | Not rated | -1.9 | -60.54% |
Outlook Therapeutics, Inc. NASDAQ:OTLK | $106.24M | $0.44 | Not rated | -2.1 | -78.67% |
NRx Pharmaceuticals, Inc. NASDAQ:NRXP | $103.04M | $2.38 | Not rated | -5.3 | +25.62% |
Equillium, Inc. NASDAQ:EQ | $95.75M | $1.51 | Not rated | -15.3 | +10.89% |
vTv Therapeutics Inc. NASDAQ:VTVT | $83.15M | $21.03 | Not rated | 128.7 | -48.11% |
Werewolf Therapeutics, Inc. NASDAQ:HOWL | $49.09M | $1.01 | Not rated | -1.4 | +20.51% |
OS Therapies Incorporated AMEX:OSTX | $46.81M | $1.00 | Not rated | -2.0 | -29.01% |
Gain Therapeutics, Inc. NASDAQ:GANX | $43.93M | $1.03 | Not rated | -3.6 | -58.60% |
Continue the stock analysis
Jump to another research area for this company.